论文部分内容阅读
为观察早期应用东菱克栓酶（ＤＦ－５２１）对脑梗塞近期疗效的影响。设ＤＦ－５２１治疗组及常规治疗组各４０例。前者除常规治疗外，在早期应用了ＤＦ－５２１治疗。出院时治愈率分别为５２．５％及３０％，显效治愈率分别为８５％及５７．５％。两组平均住院天数分别为２０．９±７．４及２５．２±６．５天。结果提示早期应用ＤＦ－５２１能明显提高脑梗塞的疗效，改善病残程度，还能明显缩短住院天数。因此，早期应用ＤＦ－５２１结合其它常规综合治疗，不失为脑梗塞的一种较好治疗方法。
In order to observe the effect of early use of rhubarb thrombin (DF-521) on the short term curative effect of cerebral infarction. The DF-521 treatment group and conventional treatment group were 40 cases. The former in addition to conventional treatment, the early application of DF-521 treatment. The cure rates at discharge were 52.5% and 30%, respectively, and the effective cure rates were 85% and 57.5% respectively. The mean length of stay in both groups was 20.9 ± 7.4 and 25.2 ± 6.5 days, respectively. The results suggest that the early application of DF-521 can significantly improve the efficacy of cerebral infarction, improve the degree of illness, but also significantly reduce the length of stay. Therefore, the early application of DF-521 combined with other conventional comprehensive treatment, after all, a better treatment of cerebral infarction.